THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.7] ID: TIP-MED-000135 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Ceftriaxone Sodium

Active Ingredient / Scientific Identity: Ceftriaxone Sodium • Class: Third-Generation Parenteral Cephalosporin Beta-Lactam Antibiotic (Long-Acting Bactericidal; WHO 'Watch' Group)

⚖️ Compare Profile
Generic / Entity NameCeftriaxone Sodium ([8.7])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassThird-Generation Parenteral Cephalosporin Beta-Lactam Antibiotic (Long-Acting Bactericidal
Available Dosage FormsSterile Powder for IV/IM Injection: 250 mg, 500 mg, 1 g (1000 mg), 2 g vials
Regulatory ClassificationSchedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register un
Key Warning & Review DateRenal & Hepatic: Unique Dual Elimination (~55% renal unchanged + ~45% biliary excretion)! Therefore, unlike other cephalospor
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H1 Prescription Drug (Mandatory Red-Bordere🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Ceftriaxone Sodium (TIP-MED-000135, Reference Code [8.7]) is classified under Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Third-Generation Parenteral Cephalosporin Beta-Lactam Antibiotic (Long-Acting Bactericidal; WHO 'Watch' Group). Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.7], p. 96): Monocef (Aristo), Oframax (Sun Pharma), Gramocef (Micro Labs), Xone (Alkem), Ceftriaxone generics; In FDC with Sulbactam/Tazobactam: Monocef-SB, Magnex/Montaz — Strengths & Dosage Forms: Sterile Powder for IV/IM Injection: 250 mg, 500 mg, 1 g (1000 mg), 2 g vials
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.7], p. 96): Monocef (Aristo), Oframax (Sun Pharma), Gramocef (Micro Labs), Xone (Alkem), Ceftriaxone generics; In FDC with Sulbactam/Tazobactam: Monocef-SB, Magnex/Montaz — Strengths & Dosage Forms: Sterile Powder for IV/IM Injection: 250 mg, 500 mg, 1 g (1000 mg), 2 g vials
Dosage Forms & Available Strengths:
Sterile Powder for IV/IM Injection: 250 mg, 500 mg, 1 g (1000 mg), 2 g vials
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Third-Generation Parenteral Cephalosporin Beta-Lactam Antibiotic (Long-Acting Bactericidal; WHO 'Watch' Group) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Third-Generation Parenteral Cephalosporin Beta-Lactam Antibiotic (Long-Acting Bactericidal; WHO 'Watch' Group) for Moderate-to-severe community-acquired pneumonia, complicated pyelonephritis/urosepsis, complicated enteric fever (typhoid), acute bacterial meningitis (2 g IV every 12 h), intra-abdominal/biliary infections, severe skin/soft-tissue infections, gonorrhoea (IM), and surgical prophylaxis..

4. Therapeutic Indications & Evidence-Supported Uses

  • Moderate-to-severe community-acquired pneumonia, complicated pyelonephritis/urosepsis, complicated enteric fever (typhoid), acute bacterial meningitis (2 g IV every 12 h), intra-abdominal/biliary infections, severe skin/soft-tissue infections, gonorrhoea (IM), and surgical prophylaxis

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: 1 g to 2 g once daily (every 24 hours) IV or deep IM (or 1 g every 12 hours; in bacterial meningitis: 2 g IV every 12 hours; maximum 4 g/day). Exceptionally long elimination half-life (6–9 hours) allows once-daily parenteral dosing in OPD/day-care settings. Follow physician prescription.

Administration & Meal Timing: Parenteral administration (IV or deep IM); independent of food. | Once daily (every 24 hours) or every 12 hours per hospital/day-care schedule.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal & Hepatic: Unique Dual Elimination (~55% renal unchanged + ~45% biliary excretion)! Therefore, unlike other cephalosporins, no dose adjustment is required in isolated renal impairment (even in ESRD/dialysis) for doses up to 2 g/day! However, in combined severe renal AND hepatic failure (or doses >2 g/day in ESRD), do not exceed 2 g/day and monitor closely.
Elimination & Renal Adjustment:
Renal & Hepatic: Unique Dual Elimination (~55% renal unchanged + ~45% biliary excretion)! Therefore, unlike other cephalosporins, no dose adjustment is required in isolated renal impairment (even in ESRD/dialysis) for doses up to 2 g/day! However, in combined severe renal AND hepatic failure (or doses >2 g/day in ESRD), do not exceed 2 g/day and monitor closely.
Hepatic Impairment Considerations:
Renal & Hepatic: Unique Dual Elimination (~55% renal unchanged + ~45% biliary excretion)! Therefore, unlike other cephalosporins, no dose adjustment is required in isolated renal impairment (even in ESRD/dialysis) for doses up to 2 g/day! However, in combined severe renal AND hepatic failure (or doses >2 g/day in ESRD), do not exceed 2 g/day and monitor closely.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • FATAL CALCIUM PRECIPITATION CONTRAINDICATION: Ceftriaxone must NEVER be reconstituted with or co-administered simultaneously (even via different infusion lines in neonates <28 days, or in the same Y-site/infusion bag in adults!) with Calcium-containing IV solutions such as Ringer's Lactate (Hartmann's Solution) or IV Calcium Gluconate! (Forms insoluble Ceftriaxone–Calcium crystalline precipitates in the lungs and kidneys!). Also contraindicated in hyperbilirubinaemic neonates (displaces bilirubin from albumin causing kernicterus) and severe beta-lactam allergy.

Key Clinical Precautions: Renal & Hepatic: Unique Dual Elimination (~55% renal unchanged + ~45% biliary excretion)! Therefore, unlike other cephalosporins, no dose adjustment is required in isolated renal impairment (even in ESRD/dialysis) for doses up to 2 g/day! However, in combined severe renal AND hepatic failure (or doses >2 g/day in ESRD), do not exceed 2 g/day and monitor closely.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Induration and pain at IM injection site (IM injection is reconstituted with 1% Lidocaine—never give the Lidocaine-reconstituted IM vial intravenously!), loose stools/diarrhoea, eosinophilia, reversible biliary pseudolithiasis ('gallbladder sludge' of calcium-ceftriaxone salt on ultrasound).
  • Anaphylaxis, Immune-Mediated Haemolytic Anaemia (can be severe/fatal), biliary colic/cholecystitis and urolithiasis (renal ceftriaxone stones), C. difficile colitis, encephalopathy/non-convulsive status epilepticus (at >2–4 g/day in elderly patients with combined hepatorenal failure).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Incompatible with Ringer's Lactate, IV Calcium Gluconate/Chloride, Vancomycin, and Aminoglycosides in the same line/syringe! Potentiates Warfarin/Acitrom INR markedly

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: When dispensing Monocef vials to a patient/attendant for OPD nursing injection: (1) Verify whether the vial was packed for IV use (Sterile Water for Injection ampoule) vs IM use (1% Lignocaine ampoule—Lignocaine must NEVER enter a vein!); (2) Remind nursing staff never to mix with Ringer's Lactate; (3) Advocate early step-down to oral therapy once the patient is afebrile and taking oral fluids.
  • Meal & Clock Timing Instruction: Parenteral administration (IV or deep IM); independent of food. (Once daily (every 24 hours) or every 12 hours per hospital/day-care schedule.)
  • Missed Dose Protocol: Administered by healthcare professionals on a 12- or 24-hour schedule.
  • Geriatric Dispensing Pearl: Because ceftriaxone has dual biliary + renal clearance, 1 g IV OD is widely and safely used in elderly CKD patients with pyelonephritis or pneumonia without needing renal dose reduction, though monitor INR closely if on warfarin.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Sterile Powder for IV/IM Injection: 250 mg, 500 mg, 1 g (1000 mg), 2 g vials

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.7] (p. 96)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.